Health Freedom Protection Act, take two
This article was originally published in The Tan Sheet
Ron Paul, R-Texas, and others reintroduced the Health Freedom Protection Act, H.R. 2117, May 1. Paul first introduced the bill in November 2005 (1"The Tan Sheet" Nov. 14, 2005, p. 10). The bill seeks to amend the Food, Drug and Cosmetic Act to allow broader dietary supplement claims, even venturing into the drug arena. The bill also seeks a more rapid response to health claims - after 100 days if there is no response from the HHS secretary the claims would be allowed. The legislation also proposes FTC must notify advertisers before the agency conducts an investigation and give 30 days for companies to discontinue their ads...
You may also be interested in...
A bill introduced in Congress Nov. 9 would "prevent FDA from disallowing structure function claims that include terms that refer to signs or symptoms of disease so long as the disease itself is not mentioned.
BridgeBio Pharma’s affiliate QED Therapeutics granted and Helsinn Group exclusive global rights (excluding Greater China) to the FGFR1-3 inhibitor infigratinib in oncology and all other indications except skeletal dysplasias (including achondroplasia). BridgeBio could see up to $2.45bn in payments from the deal, including over $100m in up-front, regulatory, and launch payments, and the remainder in sales milestones. In the month’s top M&A, Amgen entered into an agreement to acquire fellow public biotech Five Prime Therapeutics for about $1.9bn, gaining Phase III-ready bemarituzumab for frontline advanced gastric or gastroesophageal junction cancer.
Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.